Incident HFpEF and time-dependent changes in markers of LVDD severity in women and men with preclinical LVDD

Background The progression of left ventricular diastolic dysfunction (LVDD) over time may lead to the development of heart failure with preserved ejection fraction (HFpEF). HFpEF is twice as common in women compared with men; however, the sex-specific progression from LVDD towards HFpEF is poorly de...

Full description

Saved in:
Bibliographic Details
Main Authors: N Charlotte Onland-Moret, Frans H Rutten, Arco J Teske, Roxana Menken, Hester M den Ruijter, M Louis Handoko, Marianne C Verhaar, Dirk J Duncker, Maarten Jan Cramer, Anne Margje Lisa Naomi van Ommen, Elisa Dal Canto, Ernest Diez Benavente, Karim Taha
Format: Article
Language:English
Published: BMJ Publishing Group 2025-05-01
Series:Open Heart
Online Access:https://openheart.bmj.com/content/12/1/e003105.full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850204088035180544
author N Charlotte Onland-Moret
Frans H Rutten
Arco J Teske
Roxana Menken
Hester M den Ruijter
M Louis Handoko
Marianne C Verhaar
Dirk J Duncker
Maarten Jan Cramer
Anne Margje Lisa Naomi van Ommen
Elisa Dal Canto
Ernest Diez Benavente
Karim Taha
author_facet N Charlotte Onland-Moret
Frans H Rutten
Arco J Teske
Roxana Menken
Hester M den Ruijter
M Louis Handoko
Marianne C Verhaar
Dirk J Duncker
Maarten Jan Cramer
Anne Margje Lisa Naomi van Ommen
Elisa Dal Canto
Ernest Diez Benavente
Karim Taha
author_sort N Charlotte Onland-Moret
collection DOAJ
description Background The progression of left ventricular diastolic dysfunction (LVDD) over time may lead to the development of heart failure with preserved ejection fraction (HFpEF). HFpEF is twice as common in women compared with men; however, the sex-specific progression from LVDD towards HFpEF is poorly described. Therefore, we aim to evaluate changes over time in markers of LVDD severity and HFpEF in women and men with preclinical LVDD.Methods and results We reassessed 146 participants from the HELPFul study (58% women and 42% men) with preclinical LVDD after a median follow-up of 4.3 (IQR: 3.9–4.7) years. The follow-up measurements mirrored baseline measurements, encompassing clinical examination, blood draw for biomarkers and echocardiography. We determined HFpEF incidence and report changes over time in echocardiography. Additionally, we studied how blood pressure and kidney function affected LVDD progression, including plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, using generalised mixed models. All analyses were performed for women and men combined, and sex stratified. Out of 146 participants, 15 (10%) developed HF of whom 13 had HFpEF (9 women and 4 men). Over time, mean kidney function (estimated glomerular filtration rate, eGFR) declined from 89±14.4 to 81±16.9 mL/min/1.73 m2 and median NT-proBNP plasma levels increased from 71 (IQR: 44–120) to 100 (IQR: 51–157) pg/mL. In women, a higher systolic and in men a higher diastolic blood pressure were associated with an increase in NT-proBNP plasma levels over time. Lower eGFR levels were related to increased NT-proBNP plasma levels over time in both men and women.Conclusions Our study demonstrates that only a small proportion of women and men with preclinical LVDD develop incident HF over a roughly 5-year follow-up period. High blood pressure and decreased kidney function were associated with higher levels of NT-proBNP. This highlights the need to further explore cardiorenal protection as a method to prevent HFpEF.
format Article
id doaj-art-aa5386fe88e8464ab4f64cfaf84556dc
institution OA Journals
issn 2053-3624
language English
publishDate 2025-05-01
publisher BMJ Publishing Group
record_format Article
series Open Heart
spelling doaj-art-aa5386fe88e8464ab4f64cfaf84556dc2025-08-20T02:11:21ZengBMJ Publishing GroupOpen Heart2053-36242025-05-0112110.1136/openhrt-2024-003105Incident HFpEF and time-dependent changes in markers of LVDD severity in women and men with preclinical LVDDN Charlotte Onland-Moret0Frans H Rutten1Arco J Teske2Roxana Menken3Hester M den Ruijter4M Louis Handoko5Marianne C Verhaar6Dirk J Duncker7Maarten Jan Cramer8Anne Margje Lisa Naomi van Ommen9Elisa Dal Canto10Ernest Diez Benavente11Karim Taha12Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, The NetherlandsJulius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, The NetherlandsDepartment of Cardiology, University Medical Center, Utrecht University, Utrecht, The NetherlandsCardiology Centers of the Netherlands, Utrecht, The NetherlandsLaboratory of Experimental Cardiology, University Medical Center, Utrecht University, Utrecht, The NetherlandsDepartment of Cardiology, Amsterdam University Medical Center, Amsterdam, The NetherlandsDepartment of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht University, Utrecht, The NetherlandsDepartment of Cardiology, Erasmus University Medical Center, Rotterdam, The NetherlandsDepartment of Cardiology, University Medical Center, Utrecht University, Utrecht, The NetherlandsLaboratory of Experimental Cardiology, University Medical Center, Utrecht University, Utrecht, The NetherlandsLaboratory of Experimental Cardiology, University Medical Center, Utrecht University, Utrecht, The NetherlandsLaboratory of Experimental Cardiology, University Medical Center, Utrecht University, Utrecht, The NetherlandsDepartment of Cardiology, University Medical Center, Utrecht University, Utrecht, The NetherlandsBackground The progression of left ventricular diastolic dysfunction (LVDD) over time may lead to the development of heart failure with preserved ejection fraction (HFpEF). HFpEF is twice as common in women compared with men; however, the sex-specific progression from LVDD towards HFpEF is poorly described. Therefore, we aim to evaluate changes over time in markers of LVDD severity and HFpEF in women and men with preclinical LVDD.Methods and results We reassessed 146 participants from the HELPFul study (58% women and 42% men) with preclinical LVDD after a median follow-up of 4.3 (IQR: 3.9–4.7) years. The follow-up measurements mirrored baseline measurements, encompassing clinical examination, blood draw for biomarkers and echocardiography. We determined HFpEF incidence and report changes over time in echocardiography. Additionally, we studied how blood pressure and kidney function affected LVDD progression, including plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, using generalised mixed models. All analyses were performed for women and men combined, and sex stratified. Out of 146 participants, 15 (10%) developed HF of whom 13 had HFpEF (9 women and 4 men). Over time, mean kidney function (estimated glomerular filtration rate, eGFR) declined from 89±14.4 to 81±16.9 mL/min/1.73 m2 and median NT-proBNP plasma levels increased from 71 (IQR: 44–120) to 100 (IQR: 51–157) pg/mL. In women, a higher systolic and in men a higher diastolic blood pressure were associated with an increase in NT-proBNP plasma levels over time. Lower eGFR levels were related to increased NT-proBNP plasma levels over time in both men and women.Conclusions Our study demonstrates that only a small proportion of women and men with preclinical LVDD develop incident HF over a roughly 5-year follow-up period. High blood pressure and decreased kidney function were associated with higher levels of NT-proBNP. This highlights the need to further explore cardiorenal protection as a method to prevent HFpEF.https://openheart.bmj.com/content/12/1/e003105.full
spellingShingle N Charlotte Onland-Moret
Frans H Rutten
Arco J Teske
Roxana Menken
Hester M den Ruijter
M Louis Handoko
Marianne C Verhaar
Dirk J Duncker
Maarten Jan Cramer
Anne Margje Lisa Naomi van Ommen
Elisa Dal Canto
Ernest Diez Benavente
Karim Taha
Incident HFpEF and time-dependent changes in markers of LVDD severity in women and men with preclinical LVDD
Open Heart
title Incident HFpEF and time-dependent changes in markers of LVDD severity in women and men with preclinical LVDD
title_full Incident HFpEF and time-dependent changes in markers of LVDD severity in women and men with preclinical LVDD
title_fullStr Incident HFpEF and time-dependent changes in markers of LVDD severity in women and men with preclinical LVDD
title_full_unstemmed Incident HFpEF and time-dependent changes in markers of LVDD severity in women and men with preclinical LVDD
title_short Incident HFpEF and time-dependent changes in markers of LVDD severity in women and men with preclinical LVDD
title_sort incident hfpef and time dependent changes in markers of lvdd severity in women and men with preclinical lvdd
url https://openheart.bmj.com/content/12/1/e003105.full
work_keys_str_mv AT ncharlotteonlandmoret incidenthfpefandtimedependentchangesinmarkersoflvddseverityinwomenandmenwithpreclinicallvdd
AT franshrutten incidenthfpefandtimedependentchangesinmarkersoflvddseverityinwomenandmenwithpreclinicallvdd
AT arcojteske incidenthfpefandtimedependentchangesinmarkersoflvddseverityinwomenandmenwithpreclinicallvdd
AT roxanamenken incidenthfpefandtimedependentchangesinmarkersoflvddseverityinwomenandmenwithpreclinicallvdd
AT hestermdenruijter incidenthfpefandtimedependentchangesinmarkersoflvddseverityinwomenandmenwithpreclinicallvdd
AT mlouishandoko incidenthfpefandtimedependentchangesinmarkersoflvddseverityinwomenandmenwithpreclinicallvdd
AT mariannecverhaar incidenthfpefandtimedependentchangesinmarkersoflvddseverityinwomenandmenwithpreclinicallvdd
AT dirkjduncker incidenthfpefandtimedependentchangesinmarkersoflvddseverityinwomenandmenwithpreclinicallvdd
AT maartenjancramer incidenthfpefandtimedependentchangesinmarkersoflvddseverityinwomenandmenwithpreclinicallvdd
AT annemargjelisanaomivanommen incidenthfpefandtimedependentchangesinmarkersoflvddseverityinwomenandmenwithpreclinicallvdd
AT elisadalcanto incidenthfpefandtimedependentchangesinmarkersoflvddseverityinwomenandmenwithpreclinicallvdd
AT ernestdiezbenavente incidenthfpefandtimedependentchangesinmarkersoflvddseverityinwomenandmenwithpreclinicallvdd
AT karimtaha incidenthfpefandtimedependentchangesinmarkersoflvddseverityinwomenandmenwithpreclinicallvdd